TMH:dv 6395-64907 219327.doc 09/1£/03

KLARQUIST SPARKMAN, LLP

16th Floor World Trade Center, 121 S.W. Salmon Street, Portland, Oregon 97204 U.S.A.

PHONE: 503-226-7391 FAX: 503-228-9446

OFFICIAL

PLEASE DELIVER DIRECTLY TO EXAMINER JEFFREY S. PARKIN

Fax No.: (703) 872-9306

Total No. Pages: 5 including this cover sheet

Message: Transmitted herewith for filing in the above-identified application are: (1) a

Response to Restriction Requirement, and (2) supporting documents, including a copy of a PAIR status page for this application, dated September 18, 2003. If you do not receive all pages, or if you have problems receiving transmittal, please call Tanya M. Harding, Ph.D. at (503) 226-7391. The fee (large entity) has been

calculated as shown below.

In re application of: Chang

Application No. 09/701,536

Filed: June 18, 2001 Confirmation No. 5492

NUCLEIC ACID VACCINES FOR

PREVENTION OF FLAVIVIRUS

INFECTION

Examiner: Jeffrey S. Parkin

Art Unit: 1642

Attorney Reference No. 6395-64907

CERTIFICATE OF FACSIMILE

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being facsimile transmitted to fax number (703) 822-9306 on the date shown below.

Attorney for Applicant(s)

Fanya M. Harding, Ph.D

Date Transpritted: September 18, 20

FEE CALCULATION FOR CLAIMS AS AMENDED						
For	No. after amendment	No. paid for previously		Extra	Rate	Fee
Total Claims	. 42	- 42*	=	8	\$18.00	\$ 0.00
Indep.	1	- 4**	=	0	\$84.00	\$ 0.00
TOTAL FEE FOR THIS AMENDMENT						\$ 0.00

^{*}greater of twenty or number for which fee has been paid. **greater of three of number for which fee has been paid.

Please charge any additional fees that may be required in connection with filing of these documents to Deposit Account 02-4550.

Tanya M. Harding, Ph.D.

Registration No. 42,630

cc: Docketing

September 18, 2003

Date

THE INFORMATION CONTAINED IN THIS TRANSMISSION IS CONFIDENTIAL AND ONLY FOR THE INTENDED RECIPIENT IDENTIFIED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION OR USE OF THIS COMMUNICATION IS UNLAWFUL. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE (COLLECT), RETURN THE ORIGINAL MESSAGE TO US, AND RETAIN NO COPY.

KLARQUIST SPARKMAN

Attorney Reference Number 639 CENTRAL FAX CEN Application Number 09/701,536 SEP 2 2 2003

TMH:dv 09/18/03 **PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In reapplication of: Chang

Application No. 09/701,536

Filed: June 18, 2001 Confirmation No. 5492

NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS

INFECTION

Examiner: Jeffrey S. Parkin

Art Unit: 1642

Attorney Reference No. 6395-64907

COMMISSIONER FOR PATENTS P.O. BOX 1450

ALEXANDRIA, VA 22313-1450

CERTIFICATE OF FACSIMILE

I hereby certify that this paper and the documents as being attached or enclosed herewith are being face transmitted to fax number 703-872-9306 on the date

Artomey for Applicat

Date Transmitted: September 18,

RESPONSE TO RESTRICTION REQUIREMENT AND REQUEST TO RESCIND

This paper is being filed in response to a Restriction Requirement dated September 3, 2003. Applicants respectfully request that the Restriction Requirement be rescinded in this matter, as Applicants believe it is in error.

In support of this Response, Applicants submit a copy of PAIR status page for this application, dated September 18, 2003 (Exhibit A). Exhibit A is attached hereto after page 3 of this Response.